Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15274500 | 0.90 | ALDH1A1 (0.58) | NPC1ALDH1A1NFKB1RAB9ANFKB2 | |
| SCHEMBL20662905 | 0.90 | ALDH1A1 (0.58) | NPC1ALDH1A1NFKB1RAB9ANFKB2 | |
| SCHEMBL152530 | 0.88 | ALDH1A1 (0.59) | NPC1ALDH1A1NFKB1RAB9ANFKB2 | |
| SCHEMBL28360518 | 0.86 | ALDH1A1 (0.58) | NPC1ALDH1A1NFKB1RAB9ANFKB2 | |
| SCHEMBL28163372 | 0.84 | KCNH2 (0.52) | ALDH1A1KDM4EKCNH2PRMT6L3MBTL1 | |
| SCHEMBL1334921 | 0.84 | KCNH2 (0.59) | ALDH1A1KDM4EKCNH2PRMT6L3MBTL1 | |
| SCHEMBL153096 | 0.82 | PRMT6 (0.54) | NPC1ALDH1A1NFKB1RAB9ANFKB2 | |
| SCHEMBL27961808 | 0.82 | PRMT6 (0.47) | KCNH2PRMT6LTA4HADORA1CYP2E1 | |
| SCHEMBL28811791 | 0.81 | ABL1 (0.51) | NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL27961788 | 0.81 | KCNH2 (0.50) | KDM4EKCNH2PRMT6LTA4HMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4387603-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-118103038-A | 17 Beta-hydroxysteroid dehydrogenase 13 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023023310-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | NPC1 472/4885ALDH1A1 125/4885NFKB1 1598/4885 |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | HSD17B1, HSD17B13, HSD17B3 | NPC1 472/4885ALDH1A1 125/4885NFKB1 1598/4885 |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | HSD17B1, HSD17B13, HSD17B3 | NPC1 472/4885ALDH1A1 125/4885NFKB1 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.